SABS - SAB Bio posts positive data from phase 3 trial of SAB-185 in patients with COVID-19
2023-04-26 09:24:28 ET
- SAB Biotherapeutics ( NASDAQ: SABS ) reported encouraging top-line outcomes from the Phase 3 National Institutes of Health's ACTIV-2 study.
- The study evaluated the effectiveness of SAB-185 in high-risk individuals with COVID-19 who were not hospitalized, to determine whether it could prevent severe outcomes.
- According to trial data, SAB-185 exhibited a positive impact on sustained symptom resolution in participants with Omicron-caused COVID-19 compared to those who were administered the monoclonal antibody combination, REGEN-COV (casirivimab and imdevimab).
- The trial showed that 66% of the participants who received SAB-185 achieved complete symptom resolution for a minimum of 4 continuous days by Day 28, whereas only 50% of the participants treated with REGEN-COV met this endpoint.
- For the non-Omicron population, the median time it took for symptoms to completely resolve for at least 4 consecutive days was 7 days shorter with SAB-185 compared to REGEN-COV, although this difference did not reach statistical significance. Additionally, the median time it took for symptom resolution for at least 2 consecutive days was 4 days shorter for SAB-185, but this result was also not statistically significant.
- Press Release
For further details see:
SAB Bio posts positive data from phase 3 trial of SAB-185 in patients with COVID-19